West Pharmaceutical Services (WST) Non-Current Assets (2009 - 2026)

West Pharmaceutical Services' Non-Current Assets history runs 18 years deep, the most recent figure standing at $2.3 billion for Q1 2026.

• In Q1 2026, Non-Current Assets rose 5.66% year-over-year to $2.3 billion; the TTM figure through Mar 2026 stood at $9.1 billion (up 8.72% YoY), while the FY2025 annual figure was $2.3 billion, up 8.86% from the prior year.
• Non-Current Assets came in at $2.3 billion for Q1 2026 at West Pharmaceutical Services, roughly flat from $2.3 billion in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $2.3 billion in Q4 2025 to a low of $1.6 billion in Q3 2022.
• A 5-year average of $2.0 billion and a median of $1.9 billion in 2024 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets climbed 2.52% in 2022 and increased 19.19% in 2024, its largest moves.
• West Pharmaceutical Services' Non-Current Assets stood at $1.7 billion in 2022, then climbed by 11.54% to $1.9 billion in 2023, then climbed by 11.21% to $2.1 billion in 2024, then climbed by 8.86% to $2.3 billion in 2025, then dropped by 0.38% to $2.3 billion in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $2.3 billion, $2.3 billion, and $2.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison